PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8737906-1 1996 Flinders Sensitive Line hypercholinergic rats, which exhibit augmented hypothermic responses to the cholinesterase inhibitor physostigmine and to the muscarinic agonist oxotremorine, have been proposed to represent a useful animal model for some aspects of human depression. Physostigmine 125-138 butyrylcholinesterase Rattus norvegicus 100-114 9139239-7 1996 However, the physostigmine-induced inhibition of ChE could be readily reversed by further substrate addition. Physostigmine 13-26 butyrylcholinesterase Rattus norvegicus 49-52 8825739-3 1996 For this study, physostigmine was administered ip at doses of 0.05, 0.2 or 1.0 mg/kg, resulting in average cholinesterase inhibition in plasma (28, 38 and 70%), erythrocytes (19, 24 and 36%), and brain (2, 10 and 31%) which correlated well with increased total power and amplitude changes. Physostigmine 16-29 butyrylcholinesterase Rattus norvegicus 107-121 9033122-2 1996 The cholinesterase inhibitor eserine (10 microM) decreased field responses by 20 +/- 2%. Physostigmine 29-36 butyrylcholinesterase Rattus norvegicus 4-18 8890920-2 1996 In conscious rats, the dose-response curves of muscarinic agonists arecoline and pilocarpine, cholinesterase inhibitors soman and physostigmine rather than GABA receptor antagonist pentylenetetrazol or glycine receptor antagonist strychnine for producing EEG seizures were shifted leftwards by acutely repeated injections of nicotine. Physostigmine 130-143 butyrylcholinesterase Rattus norvegicus 94-108 8588286-3 1995 For this study, physostigmine was administered ip at doses of 0.05, 0.2 or 1.0 mg/kg, resulting in average cholinesterase inhibition in plasma (28, 38 and 70%), erythrocytes (19, 24 and 36%), and brain (2, 10 and 31%) which correlated well with increased total power and amplitude changes. Physostigmine 16-29 butyrylcholinesterase Rattus norvegicus 107-121 7562554-1 1995 In previous investigations, we have demonstrated that cholinesterase inhibitors such as physostigmine (PHY) and heptylphysostigmine (HEP) elicit a significant and simultaneous increase in acetylcholine (ACh) and norepinephrine (NE) levels in the rat cortex. Physostigmine 88-101 butyrylcholinesterase Rattus norvegicus 54-68 7562554-1 1995 In previous investigations, we have demonstrated that cholinesterase inhibitors such as physostigmine (PHY) and heptylphysostigmine (HEP) elicit a significant and simultaneous increase in acetylcholine (ACh) and norepinephrine (NE) levels in the rat cortex. Physostigmine 103-106 butyrylcholinesterase Rattus norvegicus 54-68 8539321-2 1995 Specifically, we compared the activity of ondansetron to that of the cholinesterase inhibitor physostigmine in attenuating two distinct cognitive deficits in the Morris water maze. Physostigmine 94-107 butyrylcholinesterase Rattus norvegicus 69-83 7870192-8 1994 produced significant, prolonged and dose-dependent increases (4 and 12 times the control value, respectively), the peak effect occurring within 1 h. Perfusion with 10 mumol/l physostigmine produced an about 30-fold increase of ACh output, suggesting that the basal extracellular ACh concentration is highly dependent on ChE activity. Physostigmine 175-188 butyrylcholinesterase Rattus norvegicus 320-323 7870192-9 1994 When ChE was inhibited locally by perfusion with physostigmine, THA (5 mg/kg) produced a transient and, at its maximum, a 1.42-fold increase in extracellular ACh concentration. Physostigmine 49-62 butyrylcholinesterase Rattus norvegicus 5-8 7861669-2 1994 The Ch/ACh ratio in CSF perfused with Ringer"s solution (30 microliters/30 min) containing 10(-5) M physostigmine, a centrally active cholinesterase inhibitor, was significantly lower than that in unprocessed CSF due to significantly higher ACh levels in the former. Physostigmine 100-113 butyrylcholinesterase Rattus norvegicus 134-148 8496822-5 1993 In the presence of THA, atropine induced a smaller increase in extracellular ACh concentrations than it did in the presence of physostigmine, under experimental conditions in which THA (100 microM) and physostigmine (10 microM) produced an equivalent effect on ChE activity. Physostigmine 202-215 butyrylcholinesterase Rattus norvegicus 261-264 8309962-1 1993 This study reports the modulatory effects of physostigmine (Phy) and concurrent acute exercise on the time course of cholinesterase (ChE) activity, the rate of decarbamylation (Kd), and half-time of recovery of ChE in red blood cells (RBC) and various tissues of rats. Physostigmine 45-58 butyrylcholinesterase Rattus norvegicus 117-131 8309962-1 1993 This study reports the modulatory effects of physostigmine (Phy) and concurrent acute exercise on the time course of cholinesterase (ChE) activity, the rate of decarbamylation (Kd), and half-time of recovery of ChE in red blood cells (RBC) and various tissues of rats. Physostigmine 45-58 butyrylcholinesterase Rattus norvegicus 133-136 8309962-1 1993 This study reports the modulatory effects of physostigmine (Phy) and concurrent acute exercise on the time course of cholinesterase (ChE) activity, the rate of decarbamylation (Kd), and half-time of recovery of ChE in red blood cells (RBC) and various tissues of rats. Physostigmine 45-58 butyrylcholinesterase Rattus norvegicus 211-214 8474626-3 1993 However, local administration of the cholinesterase inhibitors neostigmine, physostigmine or heptyl-physostigmine through the dialysis probe elevated acetylcholine above the detection limit. Physostigmine 76-89 butyrylcholinesterase Rattus norvegicus 37-51 8446666-3 1993 Soman and physostigmine both inhibit ChE, yet animals pretreated with physostigmine exhibited less ChE inhibition in serum and brain than did animals exposed to soman alone. Physostigmine 10-23 butyrylcholinesterase Rattus norvegicus 37-40 8446666-3 1993 Soman and physostigmine both inhibit ChE, yet animals pretreated with physostigmine exhibited less ChE inhibition in serum and brain than did animals exposed to soman alone. Physostigmine 70-83 butyrylcholinesterase Rattus norvegicus 37-40 8446666-3 1993 Soman and physostigmine both inhibit ChE, yet animals pretreated with physostigmine exhibited less ChE inhibition in serum and brain than did animals exposed to soman alone. Physostigmine 70-83 butyrylcholinesterase Rattus norvegicus 99-102 7871051-1 1993 Phenserine ((-)-N-phenylcarbamoyl eseroline), a carbamate analog of physostigmine (Phy), is a long-acting inhibitor of cholinesterase. Physostigmine 68-81 butyrylcholinesterase Rattus norvegicus 119-133 7871051-1 1993 Phenserine ((-)-N-phenylcarbamoyl eseroline), a carbamate analog of physostigmine (Phy), is a long-acting inhibitor of cholinesterase. Physostigmine 83-86 butyrylcholinesterase Rattus norvegicus 119-133 7871053-8 1993 Administration of the cholinesterase inhibitor physostigmine (0.1-0.4 mg/kg) induced a dose related increase in the total number of purposeless chews, but primarily these were not associated with facial tremor. Physostigmine 47-60 butyrylcholinesterase Rattus norvegicus 22-36 1426013-4 1992 Inhibitors of cholinesterase (physostigmine, diisopropylfluorophosphate) suppressed by 80% this Ca(2+)-independent efflux of [3H]acetylcholine. Physostigmine 30-43 butyrylcholinesterase Rattus norvegicus 14-28 7990271-3 1994 On the other hand, in the presence of physostigmine (50 microM; under this condition, cholinesterase activity was inhibited), tacrine did not enhance the basal ACh release. Physostigmine 38-51 butyrylcholinesterase Rattus norvegicus 86-100 7975932-9 1994 The impairment of working and reference memories in OB lesioned rats, which was assessed using a 3-panel-runway apparatus, was reduced by cholinesterase inhibitor physostigmine and NIK-247. Physostigmine 163-176 butyrylcholinesterase Rattus norvegicus 138-152 7913496-5 1994 Systemic administration of two doses of cholinesterase inhibitor [PHY (30 and 300 micrograms/kg) and HEP (2 and 5 mg/kg)] produced a dose-dependent increase in ACh levels. Physostigmine 66-69 butyrylcholinesterase Rattus norvegicus 40-54 8446666-1 1993 Continuous administration of the carbamate physostigmine, producing approximately 40% serum cholinesterase (ChE) inhibition, provides significant protection against the lethal effects of the organophosphorous nerve agent pinacolyl methylphosphonofluoridate (soman). Physostigmine 43-56 butyrylcholinesterase Rattus norvegicus 92-106 8446666-1 1993 Continuous administration of the carbamate physostigmine, producing approximately 40% serum cholinesterase (ChE) inhibition, provides significant protection against the lethal effects of the organophosphorous nerve agent pinacolyl methylphosphonofluoridate (soman). Physostigmine 43-56 butyrylcholinesterase Rattus norvegicus 108-111 8450938-1 1993 Cholinesterase inhibitors, such as physostigmine and tetrahydroaminoacridine, have been found to alleviate some of the memory deficits characteristic of senile dementia of the Alzheimer"s type (SDAT). Physostigmine 35-48 butyrylcholinesterase Rattus norvegicus 0-14 8496822-7 1993 THA (100 microM) and physostigmine (10 microM) produced an additive effect on the extracellular concentration of ACh, and the addition of THA (10 microM) to physostigmine (1 microM) produced further inhibition of in vitro ChE activity. Physostigmine 21-34 butyrylcholinesterase Rattus norvegicus 222-225 1946590-1 1991 An in vitro comparison demonstrated that the concentration of NIK-247 that inhibited cholinesterase (ChE) activities to half the normal level (ID50) was 1.3 x 10(-6) M. This value was higher than those for both physostigmine (PHY; 1.2 x 10(-7) M) and tetrahydroaminoacridine (THA; 3.6 x 10(-7) M), which are used as cholinesterase inhibitors in the treatment of cholinergic deficits. Physostigmine 211-224 butyrylcholinesterase Rattus norvegicus 101-104 1640506-1 1992 This study sought to determine the effect of heptylphysostigmine (H-PHY), a reversible cholinesterase (ChE) inhibitor with greater lipophilicity and longer duration of action than physostigmine, on resting and basal forebrain (BF)-elicited increases in cortical cerebral blood flow (CBF). Physostigmine 51-64 butyrylcholinesterase Rattus norvegicus 103-106 1507523-7 1992 The increase in working errors in hippocampal-lesioned rats was significantly reduced by treatment with the cholinesterase inhibitor physostigmine at 0.1 mg/kg and the cholinergic activating drug minaprine at 10 mg/kg. Physostigmine 133-146 butyrylcholinesterase Rattus norvegicus 108-122 1436398-6 1992 The increase in working memory errors, induced by lesions of the basolateral amygdala was significantly reduced by intraperitoneal administration of the inhibitors of cholinesterase, tetrahydroaminoacridine (0.32-1.0 mg/kg) and physostigmine (0.032-0.1 mg/kg), and the muscarinic receptor agonist, oxotremorine (0.1 mg/kg), before the runway test. Physostigmine 228-241 butyrylcholinesterase Rattus norvegicus 167-181 1594645-1 1992 Whether the pharmacodynamics of physostigmine (Phy) [rate of decarbamylation of cholinesterase (ChE) enzyme] (Kd) is altered due to acute and/or trained exercise in brain and various tissues of rat has been addressed. Physostigmine 32-45 butyrylcholinesterase Rattus norvegicus 80-94 1594645-1 1992 Whether the pharmacodynamics of physostigmine (Phy) [rate of decarbamylation of cholinesterase (ChE) enzyme] (Kd) is altered due to acute and/or trained exercise in brain and various tissues of rat has been addressed. Physostigmine 32-45 butyrylcholinesterase Rattus norvegicus 96-99 1661000-5 1991 Intrathecal administration of the cholinesterase inhibitor physostigmine produced a rapid, reversible and significant increase in the mechanical withdrawal threshold; TF latency was increased slightly but not significantly. Physostigmine 59-72 butyrylcholinesterase Rattus norvegicus 34-48 2029342-5 1991 Systemic co-administration of the cholinesterase inhibitor physostigmine (0, 0.1, 0.2 mg/kg; i.p.) Physostigmine 59-72 butyrylcholinesterase Rattus norvegicus 34-48 1700067-6 1990 A cholinesterase inhibitor, physostigmine, at doses higher than 0.1 mg/kg, s.c., significantly inhibited the HA turnover. Physostigmine 28-41 butyrylcholinesterase Rattus norvegicus 2-16 2174982-4 1990 The electrically evoked release of radioactivity was reduced by the muscarinic agonist oxotremorine and the delta selective opiate receptor agonist Metenkephalin, and was enhanced in the presence of the cholinesterase inhibitor physostigmine by the muscarinic antagonist atropine. Physostigmine 228-241 butyrylcholinesterase Rattus norvegicus 203-217 2239207-6 1990 Results showed that TTS (Transdermal Therapeutic System)-scopolamine administration facilitated habituation to rotation, whereas physostigmine, a centrally acting cholinesterase inhibitor, suppressed it, and neostigmine, a peripherally active cholinesterase inhibitor, had no effect on habituation at all. Physostigmine 129-142 butyrylcholinesterase Rattus norvegicus 163-177 2095716-0 1990 Interactive effects of physostigmine and exercise on cholinesterase activity in red blood cells and tissues of rat. Physostigmine 23-36 butyrylcholinesterase Rattus norvegicus 53-67 2095716-5 1990 In unexercised rats given physostigmine, the cholinesterase activity ranges were 73-79, 66-68, 68-74, 67-81 and 57-61% of controls from 10-30 min in red blood cells, brain, heart, diaphragm and thigh muscle, respectively. Physostigmine 26-39 butyrylcholinesterase Rattus norvegicus 45-59 2095716-6 1990 In exercised rats exposed to physostigmine, the cholinesterase activity ranges were 54-51, 58-50, 77-73, 71-83 and 54-58% of controls from 10-30 min in red blood cells, brain, heart, diaphragm and thigh muscle, respectively. Physostigmine 29-42 butyrylcholinesterase Rattus norvegicus 48-62 2095716-8 1990 Acute exercise modifies the effect of physostigmine significantly (p less than 0.01) by increasing the cholinesterase inhibition in red blood cells and brain without affecting other tissues. Physostigmine 38-51 butyrylcholinesterase Rattus norvegicus 103-117 2366261-7 1990 Structures with high cholinesterase activity (caudate-putamen, amygdala, hippocampus) showed greater retention of physostigmine over time. Physostigmine 114-127 butyrylcholinesterase Rattus norvegicus 21-35 2350265-1 1990 The purpose of this study was to see if physostigmine, a reversible cholinesterase inhibitor, affects the secretion and composition of saliva of the major salivary glands of the rat. Physostigmine 40-53 butyrylcholinesterase Rattus norvegicus 68-82 2498396-3 1989 For evaluating skin penetration of physostigmine the decrease of whole blood cholinesterase was measured. Physostigmine 35-48 butyrylcholinesterase Rattus norvegicus 77-91 20407407-4 2010 By inhibition of the cholinesterase, physostigmine increases acetylcholine and induces the cholinergic anti-inflammatory pathway. Physostigmine 37-50 butyrylcholinesterase Rattus norvegicus 21-35 2694528-8 1989 Clinically, the centrally active cholinesterase inhibitor physostigmine has been shown to give postoperative pain relief although of short duration. Physostigmine 58-71 butyrylcholinesterase Rattus norvegicus 33-47 2608162-1 1989 Heptyl-physostigmine (Heptyl-Phy; MF-201) is a new carbamate derivative of physostigmine (Phy) with greater lipophilicity and longer inhibitory action on cholinesterase (ChE) activity than the parent compound. Physostigmine 7-20 butyrylcholinesterase Rattus norvegicus 154-168 2608162-1 1989 Heptyl-physostigmine (Heptyl-Phy; MF-201) is a new carbamate derivative of physostigmine (Phy) with greater lipophilicity and longer inhibitory action on cholinesterase (ChE) activity than the parent compound. Physostigmine 7-20 butyrylcholinesterase Rattus norvegicus 170-173 2608162-1 1989 Heptyl-physostigmine (Heptyl-Phy; MF-201) is a new carbamate derivative of physostigmine (Phy) with greater lipophilicity and longer inhibitory action on cholinesterase (ChE) activity than the parent compound. Physostigmine 29-32 butyrylcholinesterase Rattus norvegicus 154-168 2608162-1 1989 Heptyl-physostigmine (Heptyl-Phy; MF-201) is a new carbamate derivative of physostigmine (Phy) with greater lipophilicity and longer inhibitory action on cholinesterase (ChE) activity than the parent compound. Physostigmine 29-32 butyrylcholinesterase Rattus norvegicus 170-173 2498396-6 1989 Ultrasound treatment also significantly increased (P less than 0.05) the inhibition of cholinesterase during the first hour after application in both physostigmine treated rats and guinea pigs: while in control guinea pigs no significant inhibition of cholinesterase could be detected during the first 2 h after application of physostigmine, the ultrasound treated group showed a 15 +/- 5% (mean +/- SEM) decrease in blood cholinesterase 1 h after ultrasound application. Physostigmine 150-163 butyrylcholinesterase Rattus norvegicus 87-101 2498396-7 1989 For physostigmine-treated rats the level of cholinesterase inhibition 1 h after ultrasound application was 53 +/- 5% in the ultrasound-treated group and 35 +/- 5% in the controls. Physostigmine 4-17 butyrylcholinesterase Rattus norvegicus 44-58 3601008-3 1987 of physostigmine are compared and the effect of two drugs producing inhibition of cholinesterase, physostigmine and metrifonate, on the activity of cholinesterase in the brain of the rat and on levels of acetylcholine (ACh) and choline (Ch). Physostigmine 98-111 butyrylcholinesterase Rattus norvegicus 82-96 3037420-5 1987 However, in the presence of the cholinesterase inhibitor physostigmine, the responses to these stimuli were greatly enhanced and this could be blocked by atropine. Physostigmine 57-70 butyrylcholinesterase Rattus norvegicus 32-46 2489433-6 1989 injection of a carbamate cholinesterase inhibitor, physostigmine, in a dose of 1.0 mg/kg resulted in a dramatic increase of the theta content in the hippocampal EEG, and in the total disappearance of the spontaneous seizures. Physostigmine 51-64 butyrylcholinesterase Rattus norvegicus 25-39 2489433-7 1989 Determination of cholinesterase activity in blood and in the brain in a separate group of subjects showed that after injection of physostigmine (1.0 mg/kg), the inhibition of this enzyme does not exceed the inhibition after injecting CVP in the doses used. Physostigmine 130-143 butyrylcholinesterase Rattus norvegicus 17-31 3691642-3 1987 administration of the cholinomimetics oxotremorine and arecoline and the cholinesterase blocker physostigmine evoked theta wave activity in the hippocampus, which was blocked by scopolamine. Physostigmine 96-109 butyrylcholinesterase Rattus norvegicus 73-87 2822903-8 1987 The cholinesterase inhibitor physostigmine (50 microM) enhanced the response produced by elevated K+ at 14, 21 and 40 days but had no effect at 2 or 7 days. Physostigmine 29-42 butyrylcholinesterase Rattus norvegicus 4-18 2890115-2 1987 In the presence of the cholinesterase inhibitor physostigmine, acetylcholine significantly (p less than 0.05-p less than 0.01) stimulated inositol phosphate formation in a concentration-related fashion: carbachol, but not oxotremorine, produced similar effects. Physostigmine 48-61 butyrylcholinesterase Rattus norvegicus 23-37 3682413-3 1987 Physostigmine, a cholinesterase inhibitor, antagonized these changes at the doses of 0.03 to 0.1 mg/kg. Physostigmine 0-13 butyrylcholinesterase Rattus norvegicus 17-31 3601008-3 1987 of physostigmine are compared and the effect of two drugs producing inhibition of cholinesterase, physostigmine and metrifonate, on the activity of cholinesterase in the brain of the rat and on levels of acetylcholine (ACh) and choline (Ch). Physostigmine 98-111 butyrylcholinesterase Rattus norvegicus 148-162 3575359-4 1987 Mecamylamine pretreatment also reduced lordotic behavior induced by bilateral intracerebroventricular (ICV) injection of the cholinesterase inhibitor, eserine (5 micrograms/cannula). Physostigmine 151-158 butyrylcholinesterase Rattus norvegicus 125-139 3028835-4 1986 Results in this communication identify several quaternary amines which are equipotent with physostigmine for inhibition of cholinesterase. Physostigmine 91-104 butyrylcholinesterase Rattus norvegicus 123-137 3588658-4 1987 All three cholinesterase inhibitors caused an initial rise in corticosterone; DFP decreased growth hormone; physostigmine reduced prolactin. Physostigmine 108-121 butyrylcholinesterase Rattus norvegicus 10-24 6771826-2 1980 A cholinesterase inhibitor, physostigmine, was administered in conjunction with imipramine to determine if these effects of imipramine were cholinergically medicated. Physostigmine 28-41 butyrylcholinesterase Rattus norvegicus 2-16 3748273-0 1986 Relation of brain regional physostigmine concentration to cholinesterase activity and acetylcholine and choline levels in rat. Physostigmine 27-40 butyrylcholinesterase Rattus norvegicus 58-72 6504953-1 1984 This paper reports the use of an RF capacitance field transducer and spectral analysis to examine the effects of the cholinesterase inhibitor physostigmine on the behavior of unrestrained rats. Physostigmine 142-155 butyrylcholinesterase Rattus norvegicus 117-131 6326923-3 1984 Compared to physostigmine, the analogues were weak inhibitors of cholinesterase enzymes. Physostigmine 12-25 butyrylcholinesterase Rattus norvegicus 65-79 6138014-2 1983 60 min before sacrifice) did not modify cholinesterase (ChE) activity, but considerably enhanced the inhibition of total ChE induced by physostigmine (PhS, 0.5 mg/kg i.p. Physostigmine 136-149 butyrylcholinesterase Rattus norvegicus 121-124 6138014-2 1983 60 min before sacrifice) did not modify cholinesterase (ChE) activity, but considerably enhanced the inhibition of total ChE induced by physostigmine (PhS, 0.5 mg/kg i.p. Physostigmine 151-154 butyrylcholinesterase Rattus norvegicus 121-124 6273940-6 1981 This THC effect was slightly increased by physostigmine, a cholinesterase inhibitor, relatively unaffected by scopolamine, a muscarinic antagonist, and almost completely blocked by ethopropazine, an anticholinergic antiparkinson drug. Physostigmine 42-55 butyrylcholinesterase Rattus norvegicus 59-73 6459593-3 1981 If cholinesterase activity was inhibited with physostigmine, the differences between the various age groups were obliterated. Physostigmine 46-59 butyrylcholinesterase Rattus norvegicus 3-17 3699340-4 1986 Physostigmine caused only slight inhibition of cholinesterase in blood and skeletal muscle. Physostigmine 0-13 butyrylcholinesterase Rattus norvegicus 47-61 3699340-5 1986 Cholinesterase activity in blood and muscle of rats pretreated with physostigmine before sarin administration was significantly higher than in tissues from rats injected with sarin alone. Physostigmine 68-81 butyrylcholinesterase Rattus norvegicus 0-14 3699340-8 1986 Effective protection against lethality by physostigmine could be related to protection of cerebral cholinesterase since inhibition of this enzyme by sarin was lowered significantly after pretreatment with physostigmine. Physostigmine 42-55 butyrylcholinesterase Rattus norvegicus 99-113 3699340-8 1986 Effective protection against lethality by physostigmine could be related to protection of cerebral cholinesterase since inhibition of this enzyme by sarin was lowered significantly after pretreatment with physostigmine. Physostigmine 205-218 butyrylcholinesterase Rattus norvegicus 99-113 4000406-8 1985 Physostigmine, an anti-cholinesterase lacking agonistic action, decreased the uptake of Ch to 73% of control at 1 mM. Physostigmine 0-13 butyrylcholinesterase Rattus norvegicus 23-37 7070215-3 1982 Neostigmine (1 microgram) and physostigmine (15 microgram) caused nearly maximal and approximately equal degrees of cholinesterase inhibition in several brain regions. Physostigmine 30-43 butyrylcholinesterase Rattus norvegicus 116-130 7070215-4 1982 The recovery of the cardiovascular parameters and of brain cholinesterase activity was significantly faster following physostigmine compared to neostigmine. Physostigmine 118-131 butyrylcholinesterase Rattus norvegicus 59-73 443426-7 1979 In contrast, physostigmine, the cholinesterase inhibitor, caused displacement of the curve to the left. Physostigmine 13-26 butyrylcholinesterase Rattus norvegicus 32-46 219652-2 1978 Physostigmine was less effective in augmenting twitch height in preparations from alloxan diabetic rats and such preparations had a significantly lowered total cholinesterase activity compared with control preparations. Physostigmine 0-13 butyrylcholinesterase Rattus norvegicus 160-174 618734-2 1978 These contractions were selectively and reversibly inhibited by carbamate-type cholinesterase inhibitors, such as neostigmine and eserine, and quaternary ammonium compounds, such as tetraethylammonium and decamethonium. Physostigmine 130-137 butyrylcholinesterase Rattus norvegicus 79-93 30389473-1 2018 Pre-administration of physostigmine can prevent poisoning against nerve agent exposure by reversibly binding to cholinesterase. Physostigmine 22-35 butyrylcholinesterase Rattus norvegicus 112-126 145765-6 1977 The blockator of cholinesterase physostigmine had opposite effects. Physostigmine 32-45 butyrylcholinesterase Rattus norvegicus 17-31 4656608-5 1972 Only slices from physostigmine-treated rats had a significantly lower cholinesterase activity.4. Physostigmine 17-30 butyrylcholinesterase Rattus norvegicus 70-84 32230733-4 2020 Comparing the protective efficacy of five such cholinesterase inhibitors (physostigmine, pyridostigmine, ranitidine, tacrine, or K-27), we observed best protection for the experimental oxime K-27. Physostigmine 74-87 butyrylcholinesterase Rattus norvegicus 47-61 30389473-15 2018 These results suggest that PEG liposomes have potential to enhance the duration of cholinesterase-protecting effect of physostigmine. Physostigmine 119-132 butyrylcholinesterase Rattus norvegicus 83-97 16216227-7 2005 Microinjection of the cholinoceptor agonist carbachol, the cholinesterase inhibitor physostigmine and the excitatory amino acid glutamate into the PHN caused increases in firing rate of AHA angiotensin-II-sensitive neurons in anesthetized WKY and SHR. Physostigmine 84-97 butyrylcholinesterase Rattus norvegicus 59-73 29796810-1 2018 Parameters of cardiac activity after administration of the cholinesterase inhibitor physostigmine were analyzed in newborn rats and on day 16 of postnatal development. Physostigmine 84-97 butyrylcholinesterase Rattus norvegicus 59-73 23736080-3 2014 The aim of this study is to investigate the effects of physostigmine, a cholinesterase inhibitor, on the intestinal microcirculation and vascular contractility in experimental endotoxemia. Physostigmine 55-68 butyrylcholinesterase Rattus norvegicus 72-86 19723529-1 2009 AIMS: It is well known that physostigmine (PHY) and other anticholinesterase (anti-ChE) agents induce hypothermia in rodents but little is known about the mechanism of action. Physostigmine 28-41 butyrylcholinesterase Rattus norvegicus 83-86 19367692-11 2009 Treatment with physostigmine resulted in at least 50% inhibition of muscle ChE activity, but produced minimal changes in the MCD values in adults or juveniles. Physostigmine 15-28 butyrylcholinesterase Rattus norvegicus 75-78 16904919-7 2007 Similarly, pre-training injections of physostigmine, a cholinesterase inhibitor, enhanced acquisition of trace conditioning in 25-day-old rats but had no effect on long-delay conditioning in rats this age (Experiment 2). Physostigmine 38-51 butyrylcholinesterase Rattus norvegicus 55-69 16118037-7 2005 The nitroprusside-induced increase of firing rate of AHA neurons was inhibited by PHN microinjection of the cholinoceptor antagonist scopolamine and potentiated by PHN microinjection of the cholinesterase inhibitor physostigmine. Physostigmine 215-228 butyrylcholinesterase Rattus norvegicus 190-204 26991753-4 2016 The objective of this study was to test the hypothesis that physostigmine, a centrally acting cholinesterase inhibitor, induces reanimation from isoflurane anesthesia in adult rats. Physostigmine 60-73 butyrylcholinesterase Rattus norvegicus 94-108 26578914-9 2015 By contrast, the muscarinic agonist oxotremorine, the cholinesterase inhibitor physostigmine, the KCNQ channel blocker XE-991, and ghrelin all increased the durations of licking bouts when infused into the mPFC. Physostigmine 79-92 butyrylcholinesterase Rattus norvegicus 54-68 22033501-8 2012 In contrast, the higher dose (100 mM solution) of atropine, the cholinergic agonist carbachol (32 mM solution), and the cholinesterase inhibitor physostigmine (13 mM solution) all decreased the number of UP states, delta power (0-3 Hz) and MUA. Physostigmine 145-158 butyrylcholinesterase Rattus norvegicus 120-134 17950890-13 2008 Inhibition of brain ChE activity occurred at dosages greater than 0.05 mg/kg physostigmine, 1mg/kg carbaryl, and 0.3 mg/kg propoxur. Physostigmine 77-90 butyrylcholinesterase Rattus norvegicus 20-23 17303509-1 2007 Previous functional investigations in rats failed to demonstrate that the classical cholinesterase inhibitor, physostigmine, can compensate for cortical cholinergic deficit induced by deafferentation from the nucleus basalis magnocellularis (NBM). Physostigmine 110-123 butyrylcholinesterase Rattus norvegicus 84-98 14751462-1 2004 Studies in animals exploring the antagonism of the cholinesterase inhibitors soman and sarin have shown that pretreatment with low doses of the centrally acting cholinesterase inhibitor, physostigmine, alone or in conjunction with the centrally acting anticholinergic agent, scopolamine, is effective against their lethality and toxicity. Physostigmine 187-200 butyrylcholinesterase Rattus norvegicus 51-65 15556140-3 2004 The doses of combinational regimen in minipumps were optimized to achieve 30-35% inhibition of blood cholinesterase activity by physostigmine and 50-100 ng/ml of blood concentrations of procyclidine as clinically available doses, respectively. Physostigmine 128-141 butyrylcholinesterase Rattus norvegicus 101-115 14751462-1 2004 Studies in animals exploring the antagonism of the cholinesterase inhibitors soman and sarin have shown that pretreatment with low doses of the centrally acting cholinesterase inhibitor, physostigmine, alone or in conjunction with the centrally acting anticholinergic agent, scopolamine, is effective against their lethality and toxicity. Physostigmine 187-200 butyrylcholinesterase Rattus norvegicus 161-175 11673119-7 2001 Physostigmine, a non-organophosphate cholinesterase inhibitor, was less effective than either chlorpyrifos or diazinon, but still caused significant inhibition of DNA synthesis in C6 cells. Physostigmine 0-13 butyrylcholinesterase Rattus norvegicus 37-51 12384257-5 2002 These responses were inhibited and enhanced by RVLM application of the muscarinic receptor antagonist scopolamine and the cholinesterase inhibitor physostigmine, respectively. Physostigmine 147-160 butyrylcholinesterase Rattus norvegicus 122-136 14521875-17 2003 Furthermore, the cholinesterase inhibitor, physostigmine, boosts ACh action during a time when cholinergic levels need to decline for proper consolidation. Physostigmine 43-56 butyrylcholinesterase Rattus norvegicus 17-31 11711044-3 2001 The cholinesterase inhibitor physostigmine at a dose of 3.2 microg/side and D-cycloserine (1.0 and 10 microg/side), which is a partial agonist acting at the glycine binding site of the NMDA receptor/channel complex, reduced the increase in working memory errors induced by 100 ng/side interleukin-1beta. Physostigmine 29-42 butyrylcholinesterase Rattus norvegicus 4-18 10411607-4 1999 5)decane-1,3-dione] hydrochloride (RS86) and the cholinesterase inhibitor physostigmine all decreased the percentage of avoidance responses at doses that produced less than approximately 30% response failures. Physostigmine 74-87 butyrylcholinesterase Rattus norvegicus 49-63 11113581-6 2000 Microinjection of the muscarinic receptor antagonist scopolamine and the cholinesterase inhibitor physostigmine into the RVLM inhibited and potentiated, respectively, the pressor response induced by PVN stimulation. Physostigmine 98-111 butyrylcholinesterase Rattus norvegicus 73-87 10698015-5 2000 Rivastigmine (0.75 and 1.5 mg/kg) and physostigmine (0.05 mg/kg) caused significantly greater ChE inhibition in females than in males (P<0.01) in the cerebral cortex, hippocampus and striatum, but not in the periphery 30 and 60 min after injection. Physostigmine 38-51 butyrylcholinesterase Rattus norvegicus 94-97 10841434-6 2000 The local application of 8-OH-DPAT into the hippocampus of lithium treated rats increased the ACh efflux in both the absence and the presence of physostigmine, a cholinesterase (ChE) inhibitor, in the perfusion fluid. Physostigmine 145-158 butyrylcholinesterase Rattus norvegicus 162-176 10841434-6 2000 The local application of 8-OH-DPAT into the hippocampus of lithium treated rats increased the ACh efflux in both the absence and the presence of physostigmine, a cholinesterase (ChE) inhibitor, in the perfusion fluid. Physostigmine 145-158 butyrylcholinesterase Rattus norvegicus 178-181 10954048-3 2000 The cholinesterase inhibitor physostigmine ( 1.0 and 3.2 microg/side) and D-cycloserine (0.32 and 1.0 microg/side), the partial agonist at the glycine binding site on the NMDA receptor/channel complex, reduced the increase in working memory errors induced by intrahippocampal 32 microg/side pyrilamine. Physostigmine 29-42 butyrylcholinesterase Rattus norvegicus 4-18 10073483-2 1999 The present study determined whether systemically administered physostigmine, a cholinesterase inhibitor, alters the rat"s ability to discern among odorant mixtures. Physostigmine 63-76 butyrylcholinesterase Rattus norvegicus 80-94 9887183-5 1999 Pretreatment with the nonspecific cholinesterase inhibitors physostigmine (0.1-0.2 mg/kg) or neostigmine (0.1 mg/kg) reduced the pressor response by diminishing the increase in systemic vascular resistance. Physostigmine 60-73 butyrylcholinesterase Rattus norvegicus 34-48 9774528-2 1998 The present study examined the impact of the centrally active cholinesterase inhibitor physostigmine, which enhances memory and central cholinergic activity, on brief shock-induced hypoalgesia on the tail-flick test using Sprague-Dawley rats. Physostigmine 87-100 butyrylcholinesterase Rattus norvegicus 62-76 10049139-2 1998 We investigated whether change in neuronal activity in cholinergic pathways mediates the anesthetic effect of the alpha2 agonist, dexmedetomidine, by determining whether physostigmine, a cholinesterase inhibitor, could antagonize the hypnotic response to dexmedetomidine in the rat and whether dexmedetomidine decreases the release of acetylcholine (ACh) in the thalamus in vivo. Physostigmine 170-183 butyrylcholinesterase Rattus norvegicus 187-201 9189894-4 1997 The increase in working memory errors induced by intrahippocampal administration of 0.32 microgram/side scopolamine to rats treated with 10 mg/kg propranolol was decreased by concurrent injection of the cholinesterase inhibitor physostigmine (3.2 micrograms/side). Physostigmine 228-241 butyrylcholinesterase Rattus norvegicus 203-217 8905730-2 1996 The increase in working memory errors induced by intrahippocampal 3.2 micrograms/side scopolamine was reduced by concurrent injection of the cholinesterase inhibitor physostigmine (1.0 and 3.2 micrograms/side. Physostigmine 166-179 butyrylcholinesterase Rattus norvegicus 141-155